The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate radiotherapy (RT) and chemotherapy (CT) treatments of early-stage extranodal natural killer/T-cell lymphoma(ENKTL).
Materials and Methods: Fifty-five patients with stage I or II ENKTL [n=39 (71%) and 16 (29%) patients, respectively] who were treated with RT between 1999 and 2013 were analyzed retrospectively. The median age was 54 years (range, 24–81). Patients were grouped by treatment modality as RT alone [n=19 (35%)], upfront CT plus RT [CT+RT, n=16 (29%)], and concurrent chemoradiotherapy[CCRT, n=20 (36%)]. The median RT dose was 48 Gy. Patient characteristics between each treatment group were well balanced.
Patterns of failure and survival were analyzed.
Results: The overall response rate after RT was 94.6%. Ten patients experienced distant failure, and seven experienced local failurecomprising five in-field and two out-field failures. The local and distant failure rates in the RT-alone group were the same (16%). In the CT+RT group, the most common failure sites were local (19%). In the CCRT group, the most common failures were distant (25%). At a median follow-up of 56 months (range, 1–178 months), the 5-year overall survival (OS) and progression-free survival rates were 66% and 54%, respectively. The 5-year OS rate for the RT-alone and CT+RT groups were 76% and 69%, respectively,and the 2-year OS rate for the CCRT group was 62% (p=0.388).
Conclusion: In the era of multimodal treatment for ENKTL, RT alone using advanced techniques should be considered for local disease control, whereas maintenance CT regimens should be considered for distant disease control.

참고문헌 (Reference)

1 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study" 대한병리학회 45 (45): 254-260, 2011

2 Kim SJ, "Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract" 47 : 1265-1273, 2006

3 Kim BS, "Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma" 42 : 779-783, 2003

4 Lee SH, "The effect of preirradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma" 91 : 427-428, 2006

5 Li YX, "Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma" 82 : 1809-1815, 2012

6 You JY, "Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan" 15 : 618-625, 2004

7 "Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT): Contents" 10 : NP-, 2010

8 Kim SJ, "Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study" 27 : 6027-6032, 2009

9 Yamaguchi M, "Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211" 27 : 5594-5600, 2009

10 Kwong YL, "Natural killer-cell malignancies: diagnosis and treatment" 19 : 2186-2194, 2005

11 Illidge T, "Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group" 89 : 49-58, 2014

12 Specht L, "Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)" 89 : 854-862, 2014

13 Wang H, "Mild toxicity and favorable prognosis of high-dose and extended involvedfield intensity-modulated radiotherapy for patients with earlystage nasal NK/T-cell lymphoma" 82 : 1115-1121, 2012

14 Wang L, "Firstline combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma" 119 : 348-355, 2013

15 Li YX, "Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy" 117 : 5203-5211, 2011

16 Isobe K, "Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters" 106 : 609-615, 2006

17 Lee J, "Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study" 24 : 612-618, 2006

18 Kim SJ, "Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study" 93 : 1895-1901, 2014

19 Shim SJ, "Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type" 67 : 31-38, 2007

20 Kim WS, "CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?" 12 : 349-352, 2001

21 Drénou B, "CD3- CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance" 89 : 2966-2974, 1997

22 Kim GE, "Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment" 18 : 54-63, 2000

23 Koom WS, "Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints" 59 : 1127-1137, 2004